Drug discovery in renal disease - Towards a more efficient framework

Toshio Miyata, Tsuyoshi Ando, Hisami Hiragi, Kanako Watanabe, Fumi Yamamoto, Douglas E. Vaughan, Tatsuo Kurokawa, Yoshiteru Oshima, Charles Van Ypersele De Strihou, Masahiro Takeuchi

Research output: Contribution to journalArticle

Abstract

The time and cost involved in bringing new drugs to the market hamper their approval. This problem is especially apparent in the case of renal diseases. Efficient drug research requires an a priori understanding of disease pathophysiology, target validation, rational and efficient drug discovery strategies and early testing of the physiological and pharmacological effects of the new agent in humans. Drug development initiated by academia benefits from international research networks and relies on internationally acceptable high-quality nonclinical data packages and bulk investigational drugs. Academics should, therefore, better understand pharmaceutical practice regulations and novel, efficient drug-development strategies. Many researchers remain unfamiliar with these areas and should collaborate with regulatory authorities to discover and validate surrogate markers for use in drug development, and to efficiently and effectively maximize the benefits and minimize the adverse effects of new drugs. The Japanese government and regulatory authorities have implemented a framework to encourage such collaborations; extension of this framework beyond its current reach is envisaged.

Original languageEnglish
Pages (from-to)290-296
Number of pages7
JournalNature Reviews Nephrology
Volume10
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Drug Discovery
Kidney
Pharmaceutical Preparations
Investigational Drugs
Research
Biomarkers
Research Personnel
Pharmacology
Costs and Cost Analysis

ASJC Scopus subject areas

  • Nephrology

Cite this

Miyata, T., Ando, T., Hiragi, H., Watanabe, K., Yamamoto, F., Vaughan, D. E., ... Takeuchi, M. (2014). Drug discovery in renal disease - Towards a more efficient framework. Nature Reviews Nephrology, 10(5), 290-296. https://doi.org/10.1038/nrneph201436

Drug discovery in renal disease - Towards a more efficient framework. / Miyata, Toshio; Ando, Tsuyoshi; Hiragi, Hisami; Watanabe, Kanako; Yamamoto, Fumi; Vaughan, Douglas E.; Kurokawa, Tatsuo; Oshima, Yoshiteru; Van Ypersele De Strihou, Charles; Takeuchi, Masahiro.

In: Nature Reviews Nephrology, Vol. 10, No. 5, 2014, p. 290-296.

Research output: Contribution to journalArticle

Miyata, T, Ando, T, Hiragi, H, Watanabe, K, Yamamoto, F, Vaughan, DE, Kurokawa, T, Oshima, Y, Van Ypersele De Strihou, C & Takeuchi, M 2014, 'Drug discovery in renal disease - Towards a more efficient framework', Nature Reviews Nephrology, vol. 10, no. 5, pp. 290-296. https://doi.org/10.1038/nrneph201436
Miyata T, Ando T, Hiragi H, Watanabe K, Yamamoto F, Vaughan DE et al. Drug discovery in renal disease - Towards a more efficient framework. Nature Reviews Nephrology. 2014;10(5):290-296. https://doi.org/10.1038/nrneph201436
Miyata, Toshio ; Ando, Tsuyoshi ; Hiragi, Hisami ; Watanabe, Kanako ; Yamamoto, Fumi ; Vaughan, Douglas E. ; Kurokawa, Tatsuo ; Oshima, Yoshiteru ; Van Ypersele De Strihou, Charles ; Takeuchi, Masahiro. / Drug discovery in renal disease - Towards a more efficient framework. In: Nature Reviews Nephrology. 2014 ; Vol. 10, No. 5. pp. 290-296.
@article{c03f05135ff64a11986b1eba96c5eb5d,
title = "Drug discovery in renal disease - Towards a more efficient framework",
abstract = "The time and cost involved in bringing new drugs to the market hamper their approval. This problem is especially apparent in the case of renal diseases. Efficient drug research requires an a priori understanding of disease pathophysiology, target validation, rational and efficient drug discovery strategies and early testing of the physiological and pharmacological effects of the new agent in humans. Drug development initiated by academia benefits from international research networks and relies on internationally acceptable high-quality nonclinical data packages and bulk investigational drugs. Academics should, therefore, better understand pharmaceutical practice regulations and novel, efficient drug-development strategies. Many researchers remain unfamiliar with these areas and should collaborate with regulatory authorities to discover and validate surrogate markers for use in drug development, and to efficiently and effectively maximize the benefits and minimize the adverse effects of new drugs. The Japanese government and regulatory authorities have implemented a framework to encourage such collaborations; extension of this framework beyond its current reach is envisaged.",
author = "Toshio Miyata and Tsuyoshi Ando and Hisami Hiragi and Kanako Watanabe and Fumi Yamamoto and Vaughan, {Douglas E.} and Tatsuo Kurokawa and Yoshiteru Oshima and {Van Ypersele De Strihou}, Charles and Masahiro Takeuchi",
year = "2014",
doi = "10.1038/nrneph201436",
language = "English",
volume = "10",
pages = "290--296",
journal = "Nature Reviews Nephrology",
issn = "1759-507X",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Drug discovery in renal disease - Towards a more efficient framework

AU - Miyata, Toshio

AU - Ando, Tsuyoshi

AU - Hiragi, Hisami

AU - Watanabe, Kanako

AU - Yamamoto, Fumi

AU - Vaughan, Douglas E.

AU - Kurokawa, Tatsuo

AU - Oshima, Yoshiteru

AU - Van Ypersele De Strihou, Charles

AU - Takeuchi, Masahiro

PY - 2014

Y1 - 2014

N2 - The time and cost involved in bringing new drugs to the market hamper their approval. This problem is especially apparent in the case of renal diseases. Efficient drug research requires an a priori understanding of disease pathophysiology, target validation, rational and efficient drug discovery strategies and early testing of the physiological and pharmacological effects of the new agent in humans. Drug development initiated by academia benefits from international research networks and relies on internationally acceptable high-quality nonclinical data packages and bulk investigational drugs. Academics should, therefore, better understand pharmaceutical practice regulations and novel, efficient drug-development strategies. Many researchers remain unfamiliar with these areas and should collaborate with regulatory authorities to discover and validate surrogate markers for use in drug development, and to efficiently and effectively maximize the benefits and minimize the adverse effects of new drugs. The Japanese government and regulatory authorities have implemented a framework to encourage such collaborations; extension of this framework beyond its current reach is envisaged.

AB - The time and cost involved in bringing new drugs to the market hamper their approval. This problem is especially apparent in the case of renal diseases. Efficient drug research requires an a priori understanding of disease pathophysiology, target validation, rational and efficient drug discovery strategies and early testing of the physiological and pharmacological effects of the new agent in humans. Drug development initiated by academia benefits from international research networks and relies on internationally acceptable high-quality nonclinical data packages and bulk investigational drugs. Academics should, therefore, better understand pharmaceutical practice regulations and novel, efficient drug-development strategies. Many researchers remain unfamiliar with these areas and should collaborate with regulatory authorities to discover and validate surrogate markers for use in drug development, and to efficiently and effectively maximize the benefits and minimize the adverse effects of new drugs. The Japanese government and regulatory authorities have implemented a framework to encourage such collaborations; extension of this framework beyond its current reach is envisaged.

UR - http://www.scopus.com/inward/record.url?scp=84899582450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899582450&partnerID=8YFLogxK

U2 - 10.1038/nrneph201436

DO - 10.1038/nrneph201436

M3 - Article

VL - 10

SP - 290

EP - 296

JO - Nature Reviews Nephrology

JF - Nature Reviews Nephrology

SN - 1759-507X

IS - 5

ER -